Bavarian Nordic Secures New Contract with U.S. Government
Bavarian Nordic A/S (Copenhagen: BAVA) has announced an important contract with the U.S. government's Biomedical Advanced Research and Development Authority (BARDA). This order, worth USD 63 million, will enhance the nation's stockpile of smallpox/mpox vaccines and pave the way for producing more freeze-dried doses of the JYNNEOS vaccine.
Enhancing Vaccine Readiness
The main goal of this contract is to strengthen the U.S. bulk vaccine supply. The need to replenish vaccines arises from the public health response to past mpox outbreaks, which ensures the production of a next-generation freeze-dried vaccine that’s crucial for U.S. preparedness against smallpox. Importantly, this agreement will facilitate the manufacture of one million freeze-dried vaccines, leveraging the new bulk inventory.
Production Timeline and Delivery Schedule
Bavarian Nordic plans to start bulk production of the vaccines soon, with an eye towards meeting international orders as part of the ongoing response to the mpox outbreak. The first deliveries of the freeze-dried doses are anticipated in 2026, reflecting a strategic effort to maintain vaccine availability and readiness.
Comments from Company Leadership
Paul Chaplin, President and CEO of Bavarian Nordic, expressed gratitude for the solid partnership with the U.S. government. He noted that this contract emphasizes their dedication to public health and the critical role that vaccines play in preparedness against infectious diseases. Chaplin also underscored the importance of equitable access to the smallpox/mpox vaccine for all countries.
Information on the JYNNEOS Vaccine
The JYNNEOS vaccine is a non-replicating smallpox/mpox vaccine that received FDA approval in 2019. It was specifically created to safeguard all populations, including those with weakened immune systems who cannot tolerate traditional vaccines that use replicating viruses. Since its approval, Bavarian Nordic has delivered nearly 30 million doses to the U.S., mainly for emergency use.
Long-Standing Collaboration with the U.S. Government
Since 2003, Bavarian Nordic has worked closely with the U.S. government, continuously innovating and supplying vaccines. With support from BARDA, they have developed a freeze-dried formulation designed to replace the current stockpile of smallpox vaccines, which offers a longer shelf life. This partnership is crucial in ensuring that public health measures are effectively in place and maintained for emergencies like the previous mpox outbreak.
Global Initiatives in Vaccine Distribution
During the 2022-2023 mpox outbreak, Bavarian Nordic successfully provided vaccine access to over 70 countries, aiding governments and organizations in their public health strategies. This global collaboration highlights the essential role of vaccine distribution and access in managing health emergencies.
About Bavarian Nordic
Bavarian Nordic is dedicated to creating innovative vaccines that aim to protect lives worldwide. The company is recognized as a leader in manufacturing smallpox and mpox vaccines and holds a diverse portfolio that includes vaccines for travelers and endemic diseases. To learn more about their initiatives and offerings, visit their website.
Frequently Asked Questions
What is the value of the contract Bavarian Nordic received?
The contract is valued at USD 63 million and is aimed at producing additional smallpox/mpox vaccines.
When will the freeze-dried doses be available?
The delivery of the freeze-dried doses is expected to take place in 2026.
Who is the primary partner for Bavarian Nordic's vaccine contracts?
Bavarian Nordic's primary partner for this contract is the U.S. government's Biomedical Advanced Research and Development Authority (BARDA).
What is the significance of the JYNNEOS vaccine?
The JYNNEOS vaccine is a non-replicating vaccine that protects against smallpox and mpox, particularly for individuals with vulnerabilities in their immune systems.
How has Bavarian Nordic contributed to addressing global health concerns?
Bavarian Nordic has assisted over 70 countries in accessing their mpox vaccine during the recent outbreak, demonstrating their commitment to global vaccine accessibility.
